Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: Profile Report

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2011 Oct 6

PMID 21970311

Authors

Monique P Curran

Affiliations

Soon will be listed here.

References

Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S . KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995; 48(2):250-8. View

Kaplan S . Side Effects of alpha-Blocker Use: Retrograde Ejaculation. Rev Urol. 2010; 11(Suppl 1):S14-8. PMC: 2812888. View

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002; 187(1):116-26. DOI: 10.1067/mob.2002.125704. View

Chapple C, Montorsi F, Tammela T, Wirth M, Koldewijn E, Fernandez Fernandez E . Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2010; 59(3):342-52. DOI: 10.1016/j.eururo.2010.10.046. View

Murata S, Taniguchi T, Takahashi M, Okada K, Akiyama K, Muramatsu I . Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 2000; 164(2):578-83. View

Roehrborn C . Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2010; 95(1):87-100. DOI: 10.1016/j.mcna.2010.08.013. View

Guimaraes S, Moura D . Vascular adrenoceptors: an update. Pharmacol Rev. 2001; 53(2):319-56. View

Marks L, Gittelman M, Hill L, Volinn W, Hoel G . Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009; 181(6):2634-40. DOI: 10.1016/j.juro.2009.02.034. View

Sausville J, Naslund M . Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. Int J Clin Pract. 2010; 64(13):1740-5. DOI: 10.1111/j.1742-1241.2010.02534.x. View

10.

Lepor H, Hill L . Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010; 30(12):1303-12. DOI: 10.1592/phco.30.12.1303. View

11.

Yoshida M, Homma Y, Kawabe K . Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007; 16(12):1955-65. DOI: 10.1517/13543784.16.12.1955. View

12.

Marks L, Gittelman M, Hill L, Volinn W, Hoel G . Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009; 74(6):1318-22. DOI: 10.1016/j.urology.2009.06.072. View

13.

Curran M . Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs. 2011; 71(7):897-907. DOI: 10.2165/11204780-000000000-00000. View